In this dual role, Dr. Roskrow’s primary responsibility is as Chief Medical Officer, managing the Company’s clinical development. The appointment is particularly important at this time as Patrys has just received approval for a first-in-human clinical trial for lead product PAT-SM6 for melanoma, which will start imminently. Dr. Roskrow will also manage the advancement of additional Patrys products into and through clinical development.
In her role as President, Dr. Roskrow will work closely with the CEO Dan Devine on corporate strategy and global business development activities. Patrys expects to benefit from her significant healthcare investment banking experience which has resulted in her having an extensive professional network within the drug development industry.
Dr. Roskrow earned with Honours a medical degree (Medicine and Surgery) and a PhD (Medicine) from the University of London. She has held many high level clinical and research positions, most recently as University Professor/ Research Group Leader in Translational Medicine at the Institute for Molecular Immunology, GSF, Munich, Germany. She has extensive experience related to the early and later-stage clinical development of promising new anti-cancer products and has published more than 30 original papers in quality peer-reviewed journals.
In her most recent role, Dr. Roskrow founded Roskrow & Partners Pty Ltd, a consulting company focussed on providing corporate and strategic advice to biotechnology and medical device companies worldwide. Previously, Dr. Roskrow was a Senior Director of Investment Banking in the Healthcare Group at Lazard Ltd where she participated in mergers & acquisitions, company financings, product out-licensing deals, R&D collaborations and transactions. She has developed an extensive network of relationships with key public and private biotechnology and pharmaceutical companies and leading clinical centres in the USA, Europe and Asia. She has served as an independent board member for two private biotechnology companies. Patrys’ CEO Dan Devine said: “This appointment strengthens the capabilities of the Company in two critical areas. Firstly, Dr. Roskrow's extensive drug development experience will benefit our current clinical stage products PAT-SM6 and PAT-SC1, and the rest of our pipeline as it advances.”
“Secondly, Dr. Roskrow's international banking experience will help Patrys in refining our corporate and business development strategies."
For further information, please contact:
Patrys Limited: Patrys Media and Investors: Daniel Devine Rebecca Wilson Chief Executive Officer Buchan Consulting P: +61 3 9670 3273 P: +61 4 1738 2391 info@patrys.com rwilson@bcg.com.au
About Patrys Limited:
Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibody therapies for cancer. Patrys has a pipeline of internal development candidates and additional products that are the subject of a collaboration agreement with a larger industry partner. More information can be found at www.patrys.com.
